2020 consensus guideline for optimal approach to the diagnosis and treatment of HER2-positive breast cancer in Bosnia and Herzegovina

Authors

  • Semir Bešlija Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina https://orcid.org/0000-0002-3066-3871
  • Zdenka Gojković University Clinical Center of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina
  • Timur Cerić Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina https://orcid.org/0000-0001-5478-8057
  • Alma Mekić Abazović Cantonal Hospital Zenica, Zenica, Bosnia and Herzegovina
  • Inga Marijanović University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina
  • Semir Vranić Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina; Current affiliation: College of Medicine, QU Health, Qatar University, Doha, Qatar https://orcid.org/0000-0001-9743-7265
  • Jasminka Mustedanagić–Mujanović University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina
  • Faruk Skenderi Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina https://orcid.org/0000-0002-2200-354X
  • Ivanka Rakita University Clinical Center of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina
  • Aleksandar Guzijan University Clinical Center of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina
  • Dijana Koprić University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina
  • Alen Humačkić Cantonal Hospital “Dr Safet Mujić”, Mostar, Bosnia and Herzegovina
  • Danijela Trokić Radiotherapy Center, International Medical Centers, Banja Luka, Bosnia and Herzegovina
  • Jasmina Alidžanović University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina
  • Alma Efendić Cantonal Hospital Zenica, Zenica, Bosnia and Herzegovina
  • Ibrahim Šišić Cantonal Hospital Zenica, Zenica, Bosnia and Herzegovina
  • Harun Drljević Cantonal Hospital Zenica, Zenica, Bosnia and Herzegovina
  • Vanesa Bešlagić Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina
  • Božana Babić University Clinical Center of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina
  • Azra Pašić Cantonal Hospital Zenica, Zenica, Bosnia and Herzegovina
  • Anela Ramić Cantonal Hospital Zenica, Zenica, Bosnia and Herzegovina
  • Dijana Mikić University Clinical Center of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina
  • Zlatko Guzin Cantonal Hospital “Dr Safet Mujić”, Mostar, Bosnia and Herzegovina
  • Dragana Karan University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina
  • Teo Buhovac University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina
  • Dragana Miletić University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina
  • Senad Šečić Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina
  • Azra Đozić Šahmić Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina
  • Lejla Mujbegović Cantonal Hospital Zenica, Zenica, Bosnia and Herzegovina
  • Alisa Kubura Cantonal Hospital Zenica, Zenica, Bosnia and Herzegovina
  • Mensura Burina University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina
  • Nenad Lalović University Hospital Foča, Foča, Bosnia and Herzegovina
  • Nikolina Dukić University Hospital Foča, Foča, Bosnia and Herzegovina
  • Jelena Vladičić Mašić University Hospital Foča, Foča, Bosnia and Herzegovina
  • Mirjana Ćuk University Hospital Foča, Foča, Bosnia and Herzegovina
  • Rajna Stanušić University Hospital Foča, Foča, Bosnia and Herzegovina

DOI:

https://doi.org/10.17305/bjbms.2020.4846

Keywords:

Her2, breast cancer, guidelines, treatment

Abstract

The HERe2Cure project, which involved a group of breast cancer experts, members of multidisciplinary tumor boards from healthcare institutions in Bosnia and Herzegovina, was initiated with the aim of defining an optimal approach to the diagnosis and treatment of HER2 positive breast cancer. After individual multidisciplinary consensus meetings were held in all oncology centers in Bosnia and Herzegovina, a final consensus meeting was held in order to reconcile the final conclusions discussed in individual meetings. Guidelines were adopted by consensus, based on the presentations and suggestions of experts, which were first discussed in a panel discussion and then agreed electronically between all the authors mentioned. The conclusions of the panel discussion represent the consensus of experts in the field of breast cancer diagnosis and treatment in Bosnia and Herzegovina. The objectives of the guidelines include the standardization, harmonization and optimization of the procedures for the diagnosis, treatment and monitoring of patients with HER2-positive breast cancer, all of which should lead to an improvement in the quality of health care of mentioned patients. The initial treatment plan for patients with HER2-positive breast cancer must be made by a multidisciplinary tumor board comprised of at least: a medical oncologist, a pathologist, a radiologist, a surgeon, and a radiation oncologist/radiotherapist.

2020 consensus guideline for optimal approach to the diagnosis and treatment of HER2-positive breast cancer in Bosnia and Herzegovina

Downloads

Additional Files

Published

01-04-2021

Issue

Section

Special Articles

Categories

How to Cite

1.
2020 consensus guideline for optimal approach to the diagnosis and treatment of HER2-positive breast cancer in Bosnia and Herzegovina. Biomol Biomed [Internet]. 2021 Apr. 1 [cited 2024 Mar. 29];21(2):120-35. Available from: https://bjbms.org/ojs/index.php/bjbms/article/view/4846